

## THE CLINICAL PROTEOMIC TUMOR ANALYSIS CONSORTIUM SCIENTIFIC SYMPOSIUM

## OCTOBER 16, 2019 NATIONAL INSTITUTES OF HEALTH BUILDING 35A, PORTER NEUROSCIENCE CENTER, ROOMS 610/620/630/640 35 CONVENT DRIVE, BETHESDA, MARYLAND 20892

The CPTAC Symposium will begin on Wednesday, October 16 at 8:30 am and will conclude at 6:00 p.m.

## **AGENDA**

| 8:00 a.m 8:30 a.m.      | Registration   |
|-------------------------|--|
| 8:30 a.m 8:40 a.m.      | Opening Remarks  Douglas R. Lowy, M.D., Director (Acting)  National Cancer Institute, NIH  |
| 8:40 a.m 9:00 a.m.      | State of CPTAC (Status Report) Henry Rodriguez, Ph.D., M.B.A. National Cancer Institute, NIH   |
| 9:00 a.m 10:30 a.m.     | Session I  |
| 9:00 a.m 9:30 a.m.      | Deep Integrated Proteogenomic Characterization of Renal Cell Carcinoma David Clark, Ph.D. Johns Hopkins University   |
| 9:30 a.m 10:00 a.m.     | Proteogenomic Characterization of Endometrial Carcinoma Emily Kawaler, M.S. New York University Langone Health   |
| 10:00 a.m 10:30 a.m.    | Proteogenomic Analysis of Pediatric Brain Tumors and Adult Glioblastoma Multiforme (CPTAC partnership with the Gabriella Miller Kids First Pediatric Research Program) Brian R. Rood, M.D. Children's National Health System |
|                         | Li Ding, Ph.D.  Washington University in St. Louis, School of Medicine   |
| 10:30 a.m. – 10:55 a.m. | Break (Group Picture)  |
| 10:55 a.m 12:10 p.m.    | Session II   |

10:55 a.m. - 11:20 a.m. Proteogenomic characterization of ovarian high-grade serous cancer implicates mitotic kinase and replication stress Karin Rodland, Ph.D. Pacific Northwest National Laboratory; Oregon Health & Science University 11:20 a.m. - 11:45 a.m. Integrated Glycoproteomic Characterization of Human High-Grade Serous Ovarian Cancer Hui Zhang, M.S., Ph.D. Johns Hopkins School of Medicine 11:45 a.m. - 12:10 p.m. Ovarian Cancer and Platinum Resistance for Clinical Trials Michael Birrer, M.D., Ph.D. University of Alabama Comprehensive Cancer Center 12:10 p.m. - 1:45 p.m. Lunch (on your own) and poster viewing 1:45 p.m.- 3:25 p.m. Session III 1:45 p.m. - 2:10 p.m. Comprehensive Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic **Opportunities** Bing Zhang, Ph.D. Baylor College of Medicine 2:10 p.m. - 2:35 p.m. Comprehensive Proteogenomic Analysis of Human Lung Adenocarcinoma Michael A Gillette, M.D., Ph.D. Broad Institute of MIT and Harvard Breast Cancer Proteogenomics for Clinical Trials 2:35 p.m. - 3:00 p.m. Matthew J. Ellis, M.B., BChir, BSc., PhD, FRCP Baylor College of Medicine Global and Phosphoproteomic Analysis to Kinase Inhibitor Treatment in Acute Myeloid 3:00 p.m. - 3:25 p.m. Leukemia (partnership with BEAT AML Master Clinical Trial) Elie Traer M.D., Ph.D. Oregon Health & Science University 3:25 p.m.- 3:45 p.m. Break 3:45 p.m.- 6:00 p.m. Session IV 3:45 p.m. - 4:10 p.m. Development of Fit-For-Purpose Targeted Mass Spec Proteomic Assays Amanda G. Paulovich, M.D., Ph.D. Fred Hutchinson Cancer Reserarch Center Towards Single Cell [Comprehensive] Proteomics 4:10 p.m. - 4:35 p.m. Tao Liu, Ph.D., Pacific Northwest National Laboratory Live Demo Workshop- Data Access and Informatic Tools 4:35 p.m.- 6:00 p.m. 4:35 p.m. - 5:15 p.m. Session 1: Data Access Proteomics: Karen Ketchum, Ph.D., ESAC, Inc. Genomics: Sharon Gaheen, Leidos Biomed Imaging: Justin Kirby, Frederick National Laboratory for Cancer Research



5:15 p.m. - 6:00 p.m.

## Session 2: Data Analysis Tool

- Data and Interactive Network Visualization for Proteogenomic Data: Mt. Sina team
- Multi-omics data analysis tool (LinkedOmics): BCM team
- Database to visualize post-translational modifications in humans (PTMcosmos): WashU team

